FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for Non-Small Cell Lung Cancer with EGFR Exon 19 Deletions or L858R Mutations By Ogkologos - October 29, 2024 1238 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MARIPOSA-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Researchers Find New, Effective Tools to Determine Breast Cancer Risk Using... December 29, 2020 Holidays and Hope When a Loved One Has Advanced Cancer December 20, 2023 Taking pride in all of our researchers November 18, 2021 Mom Thinks Baby Died Until Firefighters Say The Family Dog Made... June 4, 2019 Load more HOT NEWS Cancer Prevention Message Is Key for HPV Vaccination Discussions with Parents Why do non-smokers face delays in getting a lung cancer diagnosis? Should alcohol marketing be dropped from televised sport? Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting...
